#1 Clinical Trials Search in Europe

Study on the Effects of Satralizumab for Patients with Moderate-to-Severe Thyroid Eye Disease

3 1 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called Satralizumab in individuals with Moderate-to-Severe Thyroid Eye Disease. Thyroid Eye Disease is a condition that affects the eyes, often causing them to bulge or become swollen. The purpose of this study is to evaluate how effective and safe Satralizumab is in treating this condition. Satralizumab is administered as a solution for injection under the skin, known as a subcutaneous injection.

Participants in the study will be randomly assigned to receive either Satralizumab or a placebo, which is a substance with no active medication. The study will last for a period of 48 weeks, during which participants will receive regular injections and attend scheduled visits to monitor their progress. The main goal is to see if there is a reduction in the bulging of the eyes, known as proptosis, after 24 weeks of treatment. The study will also look at other factors, such as changes in eye appearance and quality of life, as well as any side effects that may occur.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather information on how Satralizumab affects their condition. This research aims to provide valuable insights into the treatment of Thyroid Eye Disease and potentially improve the quality of life for those affected by this condition.

1 joining the study

Upon joining the study, eligibility is confirmed based on specific criteria related to thyroid eye disease (TED).

Participants must be 18 years or older and have a clinical diagnosis of either active or chronic inactive TED.

2 initial assessment

An initial assessment is conducted to establish baseline measurements. This includes evaluating the severity of TED symptoms such as proptosis (eye bulging) and diplopia (double vision).

The clinical activity score (CAS) is used to assess the activity level of TED.

3 treatment phase

Participants receive the medication satralizumab as a subcutaneous injection. The dosage is 120 mg, administered at specified intervals.

The treatment aims to reduce symptoms of TED, such as proptosis and inflammation.

4 monitoring and follow-up

Regular follow-up visits are scheduled to monitor the response to treatment. This includes measuring changes in proptosis and CAS.

Participants are observed for any side effects or adverse events related to the treatment.

5 evaluation at week 24

At week 24, a comprehensive evaluation is conducted to assess the effectiveness of the treatment.

The primary goal is to achieve a reduction in proptosis and improvement in other TED symptoms without worsening in the other eye.

6 end of study

The study concludes with a final assessment to determine the overall impact of the treatment on TED symptoms.

Participants may receive guidance on managing TED after the study ends.

Who Can Join the Study?

  • You must be 18 years or older at the time you sign the consent form.
  • If you have active thyroid eye disease (TED), you need a clinical diagnosis showing a clinical activity score (CAS) of 3 or more in the affected eye at the start of the study. The CAS is a way to measure how active the disease is.
  • If you have chronic inactive TED, your medical records should show a CAS of less than 3 in both eyes for at least 6 months before the study starts. This means the disease has been stable and not active.
  • For chronic inactive TED, you should not have had any new symptoms or worsening of symptoms like proptosis (bulging of the eye) or diplopia (double vision) for at least 6 months before the study.
  • If you have active TED, your eye should show proptosis of 3 mm or more above normal for your race and gender. You should also have one or more of the following: lid retraction (eyelid pulled back) of 2 mm or more, moderate or severe soft tissue changes, or diplopia.
  • If you have chronic inactive TED, your eye should have a history of proptosis of 3 mm or more above normal for your race and gender, along with one or more of the following: lid retraction of 2 mm or more, moderate or severe soft tissue changes, or diplopia.
  • If you have active TED, the symptoms should have started in the affected eye 12 months or less before the study begins.
  • If you have chronic inactive TED, your initial diagnosis should have been made more than 12 months but less than 10 years before the study.
  • Your thyroid levels should be normal (euthyroid) or you should have mild hypothyroidism (low thyroid function) or hyperthyroidism (high thyroid function) that is under control.

Who Cannot Join the Study?

  • Patients who do not have Moderate-to-Severe Thyroid Eye Disease cannot participate.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are part of a vulnerable population, meaning they may need special protection or care, cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Medical University Of Vienna Vienna Austria
Azienda Ospedaliera Universitaria Federico II Di Napoli Naples Italy
Technische Universitaet Dresden Dresden Germany
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy

Other Sites

Site Name City Country Status
University Hospital Ostrava Ostrava Czechia
Budapest Retina Associates Budapest Hungary
Universitaetsklinikum Tuebingen AöR Tuebingen Germany
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Milan Italy
Philipps-Universitaet Marburg Marburg Germany
Universita’ Di Pisa Pisa Italy
Medical Center – University Of Freiburg Freiburg Im Breisgau Germany
Vseobecna Fakultni Nemocnice V Praze Prague Czechia
Deutsches Herzzentrum Berlin Berlin Germany
Azienda Socio Sanitaria Territoriale Dei Sette Laghi Varese Italy
Vfgyft Sabmsbluu ep Lxlfgdiyupno Eger Hungary
Ufnycwlsturtkhxkhkqau Mwuqocvk Atg Munster Germany
Uslcxcfrsqgbbqkgghuko Etobc Aon Essen Germany

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Austria Austria
Not recruiting
25.01.2024
Czechia Czechia
Not recruiting
25.01.2024
Germany Germany
Not recruiting
25.01.2024
Hungary Hungary
Not recruiting
25.01.2024
Italy Italy
Not recruiting
25.01.2024

Trial locations

Satralizumab is a medication being studied for its effectiveness in treating moderate-to-severe thyroid eye disease. It is administered through an injection under the skin. The trial aims to see how well this medication works in reducing the symptoms of the disease, particularly focusing on the reduction of eye bulging, which is a common symptom. The study also looks at the safety of the medication and how it behaves in the body.

Thyroid Eye Disease – Thyroid Eye Disease, also known as Graves’ orbitopathy, is an autoimmune condition where the immune system mistakenly attacks the tissues around the eyes. This leads to inflammation and swelling, causing symptoms such as bulging eyes, redness, and discomfort. As the disease progresses, it can result in increased pressure within the eye socket, affecting eye movement and vision. Patients may experience double vision and difficulty closing their eyes completely. The severity of symptoms can vary, with some individuals experiencing mild discomfort while others face significant vision problems. Over time, the disease may stabilize, but the changes in appearance and vision can persist.

Trial ID:
2023-503309-13-00
Protocol code:
GP44467
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Venetoclax plus drug combination versus drug combination alone in children with relapsed acute myeloid leukemia

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8

  • A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

    Recruiting

    3 1 1
    Investigated drugs:
    Belgium Bulgaria Denmark France Germany Greece +6